W. Qian

发表

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

J. Radford, M. Federico, M. O'Doherty, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

D. Linch, W. Qian, Paul A. Smith, 2009, Leukemia & lymphoma.

Speeding up the Evaluation of New Agents in Cancer

M. Parmar, M. Sydes, E. Eisenhauer, 2008, Journal of the National Cancer Institute.

747TiPSCHEDULING NAB-PACLITAXEL WITH GEMCITABINE (SIEGE): RANDOMISED PHASE II TRIAL TO INVESTIGATE TWO DIFFERENT SCHEDULES OF NAB-PACLITAXEL (ABX) COMBINED WITH GEMCITABINE (GEM) AS FIRST LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA (PDAC).

D. Jodrell, W. Qian, J. Valle, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gearing up software systems for genome data : a case study with SAS

N. Wareham, J. Luan, J. Zhao, 2009 .

Optimal treatment of early-stage ovarian cancer

J. Ledermann, A. Lissoni, N. Colombo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.

P. Marsden, J. Radford, P. Schleyer, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

V. Torri, M. Parmar, J. Ledermann, 2003, The Lancet.

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

J. Ledermann, C. Griffin, W. Qian, 2011, British Journal of Cancer.

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

M. Parmar, V. Torri, W. Qian, 2002, British Journal of Cancer.

A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.

J. Radford, K. Ardeshna, D. Cunningham, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis.

C. Coles, G. Wishart, N. Twyman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.

A. Hindmarsh, W. Qian, S. Prewett, 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112

D. Girling, M. Muers, W. Qian, 2004, Thorax.

Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer

T. Eisen, D. Ferry, W. Qian, 2008, Thorax.

Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.

D. Girling, R. Stephens, P. Clark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mini‐BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage‐refractory DLBCL

K. Ardeshna, I. Kayani, K. Peggs, 2012, British journal of haematology.

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

K. Ardeshna, D. Cunningham, D. Linch, 2010 .

Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes

J. Garcia-conde, J. Sierra, S. Mackinnon, 2007, British journal of haematology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

V. Torri, G. Jayson, I. Floriani, 2003, Lancet.

Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy

K. Ardeshna, P. Hoskin, W. Qian, 2012, Leukemia & lymphoma.

Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.

T. Meyer, D. Talbot, D. Cunningham, 2014, European journal of cancer.

Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL

K. Maclennan, H. Holte, P. Hoskin, 2010, British journal of haematology.

A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma

C. Burton, K. Maclennan, P. Hoskin, 2006, British Journal of Cancer.

Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non‐Hodgkin lymphoma

C. Burton, P. Hoskin, D. Cunningham, 2005, British journal of haematology.

Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib

F. Zaccagna, A. Matakidou, F. Gallagher, 2021, BJU international.

Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial

G. Follows, W. Qian, S. Sadullah, 2021, Annals of Hematology.

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

R. Stephens, K. Ardeshna, D. Cunningham, 2014, The Lancet. Oncology.

Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

P. Hoskin, T. Illidge, D. Linch, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

T. Whelan, E. Eisenhauer, H. Kitchener, 2009, The Lancet.

Capecitabine and streptozocin +/- cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial.

T. Meyer, D. Talbot, D. Cunningham, 2016 .

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

J. Larkin, R. Plummer, A. Dalgleish, 2015, Melanoma research.

Conventional second‐line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first‐line salvage therapy regimens

K. Ardeshna, S. Mackinnon, P. Hoskin, 2005, British journal of haematology.

Using Serum CA125 to Assess the Activity of Potential Cytostatic Agents in Ovarian Cancer

D. Kornbrot, S. M. Crawford, M. Hall, 2014, International Journal of Gynecologic Cancer.

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

D. Tuveson, J. Bridgewater, D. Jodrell, 2020, British Journal of Cancer.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

J. Ledermann, M. Brundage, W. Qian, 2017, Cancer.

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer

D. Girling, R. Stephens, N. Thatcher, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum: The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial (Lancet (2003) 361 (2099-106))

M. Parmar, V. Torri, H. Adams, 2003 .

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

A. Oza, M. Carey, P. Beale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma

T. Lister, J. Radford, R. Marcus, 2007 .

Rituximab With High-Dose Methotrexate In Newly Diagnosed Primary Central Nervous System Lymphoma: a Single-Center Experience From China

W. Qian, Teng Yu, Xiaohua Xu, 2022 .

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

T. A. Lister, J. Radford, P. Hoskin, 2008 .

R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma.

J. Radford, K. Ardeshna, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

M. Sydes, S. Kvaløy, H. Johnsen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, J. Radford, K. Ardeshna, 2013, The Lancet.

The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL).

P. Fayers, M. Sydes, S. Kvaløy, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingd

N. Schmitz, S. Kvaløy, H. Holte, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244

A. Pettitt, A. Horwich, P. Hoskin, 2008 .

Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial.

C. Coles, G. Wishart, N. Twyman, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

A. Pettitt, A. Horwich, P. Hoskin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial

W. Qian, Paul A. Smith, H. Eve, 2009, Leukemia & lymphoma.

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.

E. Provenzano, J. Abraham, H. Earl, 2017 .

Lymphadenectomy in endometrial cancer – Authors' reply

M. Parmar, H. Kitchener, W. Qian, 2009, The Lancet.

A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM).

W. Qian, R. Matin, S. Wordsworth, 2018, Annals of Oncology.

Re‐infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma

D. Linch, W. Qian, M. Watts, 2012, British journal of haematology.

Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer

M. Sculpher, D. Girling, R. Stephens, 2012, PharmacoEconomics.

Early versus delayed treatment of relapsed ovarian cancer

C. Griffin, W. Qian, A. Swart, 2011, The Lancet.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

A. Rossi, C. Gridelli, W. Qian, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

V. Torri, M. Parmar, J. Ledermann, 2003, The Lancet.

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

N. Rosenfeld, H. Earl, C. Parkinson, 2016, PLoS medicine.

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Corneel Coens, Alan Lamont, Gordon C Jayson, 2010, The Lancet.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

I. Tannock, M. Parmar, R. Souhami, 2002, The Lancet.

A phase 3 trial of bevacizumab in ovarian cancer.

Jacobus Pfisterer, Jalid Sehouli, Rainer Kimmig, 2011, The New England journal of medicine.

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

N. Rosenfeld, H. Earl, C. Parkinson, 2016, PLoS medicine.

Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council.

D. Girling, M. Muers, W. Qian, 2002, Seminars in oncology.

Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma

F. Zaccagna, F. Gallagher, A. Priest, 2021, PloS one.

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

W. Gregory, P. Johnson, W. Qian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial

D. Girling, R. Stephens, P. Hopwood, 2002, BMJ : British Medical Journal.

N. Schmitz, S. Kvaløy, H. Holte, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.

A. Howell, M. Parmar, J. Carmichael, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource

M. Parkes, W. Qian, T. Raine, 2020, Gut.

Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report

K. Ashkan, S. Price, K. Kurian, 2023, Journal of personalized medicine.

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

M. Stockler, A. Oza, M. Carey, 2013, The Lancet. Oncology.

Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit

T. Santarius, R. Jena, S. Price, 2017, Journal of Neuro-Oncology.

International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

M. Parmar, V. Torri, A. Lissoni, 2003, Journal of the National Cancer Institute.

and immunophenotypic criteria (MRC/NCRI LY10 trial) in patients with sporadic Burkitt lymphoma defined using cytogenetic A prospective clinicopathologic study of dose-modified CODOX-M/IVAC

S. Barrans, J. Radford, W. Qian, 2013 .

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

S. Barrans, J. Radford, W. Qian, 2008, Blood.

Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial

C. Copie-Bergman, C. Burton, F. Cavalli, 2009, British journal of haematology.

Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial.

H. Kitchener, A. Renehan, W. Qian, 2012, European journal of cancer.

Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial

A. Rosenwald, M. Ziepert, G. Ott, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

R. Booton, F. Shepherd, A. Hackshaw, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Trajectories of Haemoglobin and incident stroke risk: a longitudinal cohort study

W. Qian, F. Xue, Tao Zhang, 2019, BMC Public Health.

Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party.

P. Fayers, M. Parmar, D. Girling, 2000, Statistics in medicine.

Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.

R. Rintoul, D. Rassl, W. Qian, 2018, Lung cancer.

A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

N. Shah, E. Harrington, B. Davies, 2018 .

Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer

Patrick Royston, Mahesh K B Parmar, P. Royston, 2003, Statistics in medicine.

Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma

L. di Lisio, D. Jodrell, W. Qian, 2023, British Journal of Cancer.

The Cambridge Breast IMRT trial: comparison of clinician versus patient reported outcomes

C. Coles, W. Qian, G. Barnett, 2017 .

The Cambridge Breast Intensity-modulated Radiotherapy Trial: Comparison of Clinician- versus Patient-reported Outcomes.

C. Coles, W. Qian, C. Wilson, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

A. Oza, M. Carey, P. Beale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MA 11.02 Circulating Tumor DNA in Early Stage NSCLC: High Sensitivity Analysis in Low Burden Disease. LUCID Study Update

N. Rosenfeld, T. Eisen, R. Rintoul, 2017 .

Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer: Results of the Randomized MRC ASTEC and NCIC CTG EN.5 Trials, A Systematic Review and Meta-analysis

M. Parmar, T. Whelan, W. Qian, 2008 .

A Comparison of Outcomes Following Laparoscopic and Open Hysterectomy With or Without Lymphadenectomy for Presumed Early-Stage Endometrial Cancer: Results From the Medical Research Council ASTEC Trial

J. Warwick, W. Qian, M. Kyrgiou, 2015, International Journal of Gynecologic Cancer.

The Rockwood Geriatric Clinical Frailty Scale is a more discriminatory tool for assessing older cancer patients compared with standard oncology performance status scales

W. Qian, P. Corrie, M. Denholm, 2017 .

N. Schmitz, S. Kvaløy, H. Holte, 2001 .

Establishment of a validated central reading system for ileocolonoscopy in an academic setting

M. Parkes, S. Travis, N. Kennedy, 2022, Gut.

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

M. Parmar, H. Kitchener, W. Qian, 2009, The Lancet.

Immediate versus delayed thoracic radiotherapy (TRT) in patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) and minimal symptoms: Results of an MRC/BTS randomised trial

D. Girling, P. Hopwood, W. Qian, 2000 .

Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.

J. Larkin, R. Plummer, A. Dalgleish, 2013 .

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

S. Barrans, W. Qian, G. Mead, 2009 .

O-275 Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21)

D. Girling, N. Thatcher, W. Qian, 2003 .

Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit

T. Santarius, R. Jena, S. Price, 2017, Journal of Neuro-Oncology.

J. Warwick, W. Qian, M. Kyrgiou, 2015, International Journal of Gynecologic Cancer.

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.

E. Provenzano, J. Abraham, H. Earl, 2022, Journal of Clinical Oncology.

COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC).

C. Gridelli, F. Perrone, W. Qian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.

A. Hindmarsh, W. Qian, S. Prewett, 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.